SESN2: A Potential Drug Target and Biomarker (G83667)

Target Name: SESN2

NCBI ID: G83667

SESN2

SESN2: A Potential Drug Target and Biomarker

Sex chromosome-specific gene 2 (SESN2) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. SESN2 plays a critical role in the regulation of cell proliferation and has been implicated in the development and progression of several diseases.

SESN2 functions as a negative regulator of the insulin-like growth factor (IGF) signaling pathway, which is a critical pathway involved in cell growth, differentiation, and survival. The IGF pathway is a well-established target for many diseases, including cancer, and researchers have identified numerous mutations and variants in the IGF pathway that have been associated with cancer risk and progression. SESN2 has been shown to play a negative role in the regulation of IGF signaling by binding to the IGF-1 receptor and preventing its activation.

SESN2 has also been shown to play a role in the regulation of cell survival and apoptosis. In cancer cells, SESN2 has been shown to promote the survival of cancer cells by inhibiting cell apoptosis and activating cell proliferation. This is a critical mechanism that allows cancer cells to evade the host immune system and continue to grow and multiply.

In neurodegenerative diseases, SESN2 has been implicated in the regulation of neurotransmitter synthesis and release, as well as the regulation of neuronal survival and apoptosis. SESN2 has been shown to play a critical role in the regulation of dopamine synthesis and release, and has been linked to the development of neurodegenerative diseases such as Parkinson's disease and Huntington's disease.

In autoimmune disorders, SESN2 has been shown to play a role in the regulation of immune cell function and the regulation of inflammation. SESN2 has been shown to promote the development of autoimmune disorders by suppressing the regulation of T cell function, which is critical for the immune response.

In conclusion, SESN2 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker in a variety of diseases. SESN2's role in the regulation of the IGF signaling pathway, cell survival and apoptosis, and the regulation of neurotransmitter synthesis and release makes it an attractive target for drug development. Further research is needed to fully understand the role of SESN2 in disease and to develop effective treatments.

Protein Name: Sestrin 2

Functions: Functions as an intracellular leucine sensor that negatively regulates the TORC1 signaling pathway through the GATOR complex (PubMed:18692468, PubMed:25263562, PubMed:25457612, PubMed:26449471, PubMed:26612684, PubMed:26586190, PubMed:31586034, PubMed:35114100). In absence of leucine, binds the GATOR subcomplex GATOR2 and prevents TORC1 signaling (PubMed:18692468, PubMed:25263562, PubMed:25457612, PubMed:26449471, PubMed:26612684, PubMed:26586190, PubMed:31586034, PubMed:35114100). Binding of leucine to SESN2 disrupts its interaction with GATOR2 thereby activating the TORC1 signaling pathway (PubMed:26449471, PubMed:26586190, PubMed:35114100). This stress-inducible metabolic regulator also plays a role in protection against oxidative and genotoxic stresses. May negatively regulate protein translation in response to endoplasmic reticulum stress, via TORC1 (PubMed:24947615). May positively regulate the transcription by NFE2L2 of genes involved in the response to oxidative stress by facilitating the SQSTM1-mediated autophagic degradation of KEAP1 (PubMed:23274085). May also mediate TP53 inhibition of TORC1 signaling upon genotoxic stress (PubMed:18692468). Moreover, may prevent the accumulation of reactive oxygen species (ROS) through the alkylhydroperoxide reductase activity born by the N-terminal domain of the protein (PubMed:26612684). Was originally reported to contribute to oxidative stress resistance by reducing PRDX1 (PubMed:15105503). However, this could not be confirmed (PubMed:19113821)

The "SESN2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SESN2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets